The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kovaleva S.A.

Center for Expertise and Quality Control of Medical Care

Fedyaev D.V.

Center for Expertise and Quality Control of Medical Care;
Russian Medical Academy of Continuous Professional Education;
Research Financial Institute

Seryapina Yu.V.

Center for Expertise and Quality Control of Medical Care

Actual issues of providing and paying for medical care within compulsory medical insurance in patients with retinal diseases

Authors:

Kovaleva S.A., Fedyaev D.V., Seryapina Yu.V.

More about the authors

Journal: Medical Technologies. Assessment and Choice. 2021;43(1): 63‑72

DOI: 10.17116/medtech20214301163

Read: 3280 times

Download PDF (RU)
Contact the author
Table of contents

ACTUAL ISSUES OF PROVIDING AND PAYING FOR MEDICAL CARE WITHIN COMPULSORY MEDICAL INSURANCE IN PATIENTS WITH RETINAL DISEASES
ACTUAL ISSUES OF PROVIDING AND PAYING FOR MEDICAL CARE WITHIN COMPULSORY MEDICAL INSURANCE IN PATIENTS WITH RETINAL DISEASES

To cite this article:

Kovaleva SA, Fedyaev DV, Seryapina YuV. Actual issues of providing and paying for medical care within compulsory medical insurance in patients with retinal diseases. Medical Technologies. Assessment and Choice. 2021;43(1):63‑72. (In Russ.)
https://doi.org/10.17116/medtech20214301163

Подписка 2026 Медицинские технологии. Оценка и выбор (Medical Technologies. Assessment and Choice)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Clinical and economic impact of broader implementation of opti­cal cohe­rence tomo­graphy and anti-VEGF therapy for diabetic reti­nopathy and macu­lar edema in type 1 diabetes. Medi­cal Technologies. Asse­ssment and Choice. 2026;(1):122-133
The effect of vitrectomy on changes in mole­cular biomarker levels of the vitreous cavity in the early postoperative period in proliferative diabetic reti­nopathy. Russian Annals of Ophthalmology. 2025;(2):30-36
The effe­cts of intraoperative use of angiogenesis inhi­bitors on outcomes and complication rates in the surgical treatment of proliferative diabetic reti­nopathy. Russian Annals of Ophthalmology. 2025;(2):44-50
Arti­ficial inte­lligence in asse­ssment of indi­vidual risks of age-related macu­lar dege­neration progression. Russian Annals of Ophthalmology. 2025;(2):123-128
Pote­ntial and prospects of the astragaloside IV use for age-associated diseases prevention. Russian Journal of Preventive Medi­cine. 2025;(7):94-99
Amyloidogenesis and neurotrophic dysfunction in age-related macu­lar dege­neration in correlation with Alzheimer’s disease. Russian Journal of Archive of Pathology. 2025;(6):61-68
Mono­cyte telo­mere length as a novel biomarker of macu­lar atro­phy and response to anti-VEGF therapy in age-related macu­lar dege­neration. Russian Annals of Ophthalmology. 2025;(6):52-61
Use of fari­cimab in neovascular age-related macu­lar dege­neration and diabetic macu­lar edema in Russia. Resu­lts of the FARWATER retrospective study. Russian Annals of Ophthalmology. 2025;(6):82-91
Diabetic reti­nopathy and diabetic macu­lar edema: etiopathogenesis and vitreoretinal surgery as one of the methods of treatment. Russian Annals of Ophthalmology. 2026;(2):86-91
Abstract:

OBJECTIVE

To assess medical care (intravitreal administration of the drugs) for patients with retinal diseases in the Russian Federation, to compare availability of intravitreal administration of the drugs in Russia with this parameter in other countries, to analyze the modern payment system for specialized medical care within the basic compulsory health insurance program for this medical procedure.

MATERIAL AND METHODS

Intravitreal administration of the drugs in patients with retinal diseases in the Russian Federation was assessed using data from the registers of compulsory health insurance accounts. Payment system for intravitreal administration of the drugs was estimated considering the number of admissions by diagnosis-related group «Eye surgery (level 5)» (st21.005 and ds21.006) in the context of ICD-10 diagnoses, nomenclature of medical services, levels of medical organizations and correction factors for this diagnosis-related group. Availability of intravitreal administration of the drugs was compared with this parameter in other countries considering IQVIA (Institute for Human Data Science Reports) report on procurement of angiogenesis inhibitors and statistical data on the prevalence of age-related macular degeneration and diabetic macular edema for 2019.

RESULTS

Mean number of admissions for intravitreal administration of the drugs in Russia is 2.99 cases per 10 000. Only 35% of admissions were aimed at intravitreal administration of the drugs. One patient receives near 2.15 these procedures in Russia. Actual availability of angiogenesis inhibitors is 9.6—11.7 times lower than the required level.

CONCLUSION

We found imperfection of modern payment system for medical care in patients with retinal diseases regarding the balance of diagnosis-related group «Eye surgery (level 5)». Absence of unified approaches to planning and insufficient availability of medical care for patients with retinal diseases in the regions of Russia were also observed.

Keywords:

intravitreal administration
angiogenesis inhibitors
age-related macular degeneration
diabetic retinopathy
retinal diseases

Authors:

Kovaleva S.A.

Center for Expertise and Quality Control of Medical Care

Fedyaev D.V.

Center for Expertise and Quality Control of Medical Care;
Russian Medical Academy of Continuous Professional Education;
Research Financial Institute

Seryapina Yu.V.

Center for Expertise and Quality Control of Medical Care

Received:

22.12.2020

Accepted:

14.01.2021

Close metadata

References:

  1. Vsemirnaya organizaciya zdravoohraneniya. Vseobshchij dostup k zdorov’yu glaz: global’nyj plan dejstvij na 2014—2019 gg. 2013. Accessed January 19, 2021. (In Russ.). https://www.who.int/blindness/AP2014_19_Russian.pdf?ua=1
  2. Finger RP, Daien V, Eldem BM, et. al. Anti-vascular endothelial growth factor in neovascular age-related macular degeneration — a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems. BMC Ophthalmology. 2020;20(1):294.  https://doi.org/10.1186/s12886-020-01554-2
  3. Neroev VV. Rabota Rossijskogo nacional’nogo komiteta po likvidacii ustranimoj slepoty v ramkah programmy VOZ «Zrenie 2020». Doklad ROOF. M. 2014. Accessed January 19, 2021. (In Russ.). https://helmholtzeyeinstitute.ru/photo/02-Neroev-Doklad-na-ROOF-2014-VOZ.pdf
  4. Neroev VV. Invalidnost’ po zreniyu v Rossijskoj Federacii. Doklad Obshchestvennoj obshcherossijskoj organizacii «Associaciya vrachej-oftal’mologov». SPb. 2017. Accessed January 19, 2021. (In Russ.). https://avo-portal.ru/events/reports/item/266-invalidnost.pdf
  5. Schmidt-Erfurth U, Chong V, Loewenstein A, et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). British Journal of Ophthalmology. 2014;98(9):1144-1167. https://doi.org/10.1136/bjophthalmol-2014-305702
  6. Flaxel CJ, Adelman RA, Bailey ST, et al. Age-Related Macular Degeneration Preferred Practice Pattern. Ophthalmology. 2020;127(1):1-65.  https://doi.org/10.1016/j.ophtha.2019.09.024
  7. Age-Related Macular Degeneration. NICE Guideline. 2018. Accessed January 19, 2021. https://www.nice.org.uk/guidance/ng82/resources/agerelated-macular-degeneration-pdf-1837691334853
  8. Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, et al. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237(4):185-222.  https://doi.org/10.1159/000458539
  9. Wong TY, Sun J, Kawasaki R, et al. Guidelines on Diabetic Eye Care: The International Council of Ophthalmology Recommendations for Screening, Follow-up, Referral, and Treatment Based on Resource Settings. Ophthalmology. 2018;125(10):1608-1622. https://doi.org/10.1016/j.ophtha.2018.04.007
  10. Ghanchi F, Diabetic Retinopathy Guidelines Working Group. The Royal College of Ophthalmologists’ clinical guidelines for diabetic retinopathy: a summary. Eye. 2013;27(2):285-287.  https://doi.org/10.1038%2Feye.2012.287
  11. Corcóstegui B, Durán S, González-Albarrán MO, et al. Update on Diagnosis and Treatment of Diabetic Retinopathy: A Consensus Guideline of the Working Group of Ocular Health (Spanish Society of Diabetes and Spanish Vitreous and Retina Society). Journal of Ophthalmology. 2017;2017:8234186. https://doi.org/10.1155/2017/8234186
  12. Flaxel CJ, Adelman RA, Bailey ST, et al. Retinal Vein Occlusions Preferred Practice Pattern. Ophthalmology. 2020;127(2):288-320.  https://doi.org/10.1016/j.ophtha.2019.09.029
  13. Retinal Vein Occlusion (RVO) Guidelines. The Royal College of Ophthalmologists 2015. Accessed January 19, 2021. https://www.rcophth.ac.uk/wp-content/uploads/2015/07/Retinal-Vein-Occlusion-RVO-Guidelines-July-2015.pdf
  14. Schmidt-Erfurth U, Garcia-Arumi J, Gerendas BS, et al. Management of Retinal Vein Occlusion by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2019;242(3):123-162.  https://doi.org/10.1159/000502041
  15. Klinicheskie rekomendacii (proekt). Saharnyj diabet: retinopatiya diabeticheskaya, makulyarnyj otek diabeticheskij. 2020. Accessed January 19, 2021. (In Russ.). https://avo-portal.ru/doc/fkr/approved/item/368-saharnyy-diabet-retinopatiya-diabeticheskaya-makulyarnyy-otek-diabeticheskiy
  16. Klinicheskie rekomendacii (proekt): Vozrastnaya makulryanaya degenraciya. 2020. Accessed January 19, 2021. (In Russ.). https://avo-portal.ru/doc/fkr/approved/item/261-vozrastnaya-makulyarnaya-degeneratsiya
  17. Elaraoud I, Attawan A, Quhill F. Case Series Investigating the Efficacy and Safety of Bilateral Fluocinolone Acetonide (ILUVIEN) in Patients with Diabetic Macular Edema. Ophthalmology and Therapy. 2016;5(1):95-104.  https://doi.org/10.1007/s40123-016-0045-7
  18. Giocanti-Auregan A, Tadayoni R, Grenet T, et al. Estimation of the need for bilateral intravitreal anti-VEGF injections in clinical practice. BMC Ophthalmology. 2016;16:142.  https://doi.org/10.1186/s12886-016-0317-y
  19. Lim JH, Wickremasinghe SS, Xie J, et al. Delay to Treatment and Visual Outcomes in Patients Treated with Anti-Vascular Endothelial Growth Factor for Age-Related Macular Degeneration. American Journal of Ophthalmology. 2012;153(4):678-686.  https://doi.org/10.1016/j.ajo.2011.09.013
  20. Ying G, Huang J, Maguire MG, et al; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Baseline Predictors for One-Year Visual Outcomes with Ranibizumab or Bevacizumab for Neovascular Age-related Macular Degeneration. Ophthalmology. 2013;120(1):122-129.  https://doi.org/10.1016/j.ophtha.2012.07.042
  21. Muether PS, Hoerster R, Hermann MM, et al. Long-term effects of ranibizumab treatment delay in neovascular age-related macular degeneration. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2013;251(2):453-458.  https://doi.org/10.1007/s00417-012-2038-0
  22. Lipatov DV, Lyshkanets OI. Intravitreal therapy of diabetic macular edema in Russian Federation: current state of the problem. Vestnik oftal’mologii. 2019;135(4):128-139. (In Russ.). https://doi.org/10.17116/oftalma2019135041128
  23. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for Neovascular Age-Related Macular Degeneration. New England Journal of Medicine. 2006;355(14):1419-1431. https://doi.org/10.1056/nejmoa054481
  24. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE Study. Ophthalmology. 2011;118(4):615-625.  https://doi.org/10.1016/j.ophtha.2011.01.031
  25. Chong V. Ranibizumab for the treatment of wet AMD: a summary of real-world studies. Eye. 2016;30(11):1526. https://doi.org/10.1038/eye.2016.202
  26. Zhang Y, Chioreso C, Schweizer ML, et al. Effects of Aflibercept for Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis of Observational Comparative Studies. Investigative Ophthalmology and Visual Science. 2017;58(13):5616-5627. https://doi.org/10.1167/iovs.17-22471
  27. Hrarat L, Fajnkuchen F, Boubaya M, et al.. Outcomes after a 1-Year Treatment with Ranibizumab for Diabetic Macular Edema in a Clinical Setting. Ophthalmologica. 2016;236(4):207-214.  https://doi.org/10.1159/000453006
  28. Mitchell P, Sheidow TG, Farah ME, et al. Effectiveness and safety of ranibizumab 0.5 mg in treatment-naïve patients with diabetic macular edema: Results from the real-world global LUMINOUS study. PLoS One. 2020;15(6):e0233595. https://doi.org/10.1371/journal.pone.0233595
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.